FDA turned back ITM's experimental treatment, while Silence Therapeutics' divesiran was identified as a potential competitive threat to rusfertide.
1 report, 1 independent
Updated Aug 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA turned back ITM's experimental treatment, while Silence Therapeutics' divesiran was identified as a potential competitive threat to rusfertide.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Silence Therapeutics
UK business
- FDA